IC
TNGX icon

Ikarian Capital’s Tango Therapeutics TNGX Stock Holding History

Ikarian Capital’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,456
Closed -$42K – 201
2022
Q1 		$42K Buy
5,456
+276
+5% +$2.39K 0.01% 187
2021
Q4 		$56K Buy
+5,180
New +$62.3K 0.01% 172
2021
Q2 		– Sell
-300,250
Closed -$3.34M – 285
2021
Q1 		$3.34M Buy
300,250
+150,738
+101% +$1.73M 0.11% 162
2020
Q4 		$1.71M Buy
149,512
+149,262
+59,705% +$1.57M 0.08% 162
2020
Q3 		$2K Buy
+250
New +$2.55K ﹤0.01% 173

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Ikarian Capital's TNGX Position: Q2 2022 in Review

Ikarian Capital sold out of Tango Therapeutics (TNGX) in Q2 2022, closing a stake of 5,456 shares — an estimated $42K sold.

Ikarian Capital first reported a position in TNGX in Q3 2020 and held it in 5 quarters. The position peaked at $3.34M in Q1 2021. 77 funds tracked by Wall St. Rank hold TNGX as of Q2 2022.

  • Ikarian Capital reported no remaining Tango Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 5,456 Tango Therapeutics shares in Q2 2022, an estimated $42K.
  • Ikarian Capital first reported a position in Tango Therapeutics in Q3 2020 and held it in 5 quarters.
  • Ikarian Capital's Tango Therapeutics position peaked at $3.34M in Q1 2021.
  • 77 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.